The functional outcome of SMAD suppression depends on tumor context: in early-stage cancers where TGF-β retains growth-inhibitory activity, miR-483 relieves this brake; in advanced tumors, reduced canonical SMAD signaling may favor non-canonical, pro-invasive TGF-β outputs that promote EMT. This evidence concerns the gene TGFB1 and neoplasm.